Achilles Therapeutics plc (ACHL) has a consensus analyst rating of Buy, based on 5 analysts covering the stock. Of those, 2 recommend buying, 1 recommend holding, and 2 recommend selling.
The analyst consensus price target for ACHL is $2.00, representing a +35.1% upside from the current price of $1.48. Price targets range from a low of $2.00 to a high of $2.00.
